| Literature DB >> 35096488 |
Melanie Bourgin1,2, Oliver Kepp1,2, Guido Kroemer1,2,3.
Abstract
Vitamin B5 (panthotenic acid), the precursor of coenzyme A (CoA), is contained in most food items and is produced by the intestinal microbiota. A recent study published in Cell Metabolism reports that vitamin B5 and CoA favor the differentiation of CD8+ cytotoxic T cells into interleukin-22 (IL-22)-producing Tc22 cells, likely through fueling mitochondrial metabolism. Importantly, in a small cohort of melanoma patients, the plasma levels of vitamin B5 positively correlate with responses to PD-1-targeted immunotherapy. Moreover, in mice, supplementation with vitamin B5 increases the efficacy of PD-L1-targeted cancer immunotherapy, and in vitro culture of T cells with CoA enhances their antitumor activity upon adoptive transfer into mice. These finding suggest that vitamin B5 is yet another B vitamin that stimulates anti-cancer immunosurveillance.Entities:
Keywords: Acetyl coenzyme A; immune checkpoint inhibitor; microbiome; nicotinamide; vitamin B3
Mesh:
Substances:
Year: 2022 PMID: 35096488 PMCID: PMC8794238 DOI: 10.1080/2162402X.2022.2031500
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110
Figure 1.Immunostimulatory effects of vitamin B5 in anticancer immunotherapy. Schematic overview on the role of vitamin B5 and coenzyme A (CoA) on cancer immunotherapy targeting the PD-1/PD-L1 interaction. For details see main text.